Tratamento do carcinoma metastático
Alternative title
Treatment of the metastatic renal cell carcinomaDate
2004-04-01Type
Access rights

Metadata
Show full item recordAbstract
The renal cell carcinoma (RCC) is the seventh most common malignancy, accounting for more than 3% of cancer incidence in the United States. RCC is more common in males, occurring primarily in the 5 th to 7 th decades of life. At the time of presentation one third of the patients have advanced disease and about 50% of the patients that underwent radical nephrectomy have recurrence. With the mainstream implementation of imaging modalities, such as ultrasound, the incidental detection of RCC has dramatically increased in recent years. Patients with metastatic RCC without treatment have na average survival of 6 to 10 months, and only 10 to 20% can be expected to survive 2 years. Treatment for patients with advanced disease remains unsatisfactory and the metastatic renal cancer continue to present a therapeutic challenge systemic therapies employed in patients with this tumor include chemotherapy, hormonal therapy, and immunotherapy. The authors review the treatment strategies of the metastatic renal cell carcinoma (RCC).
How to cite this document
Keywords
Language
Collections

Related items
Showing items related by title, author, creator and subject.
-
Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy
Nars, Mariana S.; Kaneno, Ramon
(International Journal of Cancer, 2013) [Artigo]
Given that cancer is one of the main causes of death worldwide, many efforts have been directed toward discovering new treatments and approaches to cure or control this group of diseases. Chemotherapy is the main treatment ... -
Role of natural killer cells in antitumor resistance
Kaneno, Ramon(Annual Review of Biomedical Sciences, 2005) [Artigo]
Natural killer cells constitute a population of lymphocytes able to non-specifically destroy virus-infected and some kinds of tumor cells. Since this lytic activity was shown by non-immunized animals the phenomenon is ... -
Low RKIP expression associates with poor prognosis in bladder cancer patients
Afonso, Julieta; Longatto-Filho, Adhemar; Martinho, Olga; Lobo, Francisco; Amaro, Teresina; Reis, Rui M.; Santos, Lúcio L. (Virchows Archiv, 2013) [Artigo]
Urothelial bladder cancer (UBC) is a heterogeneous type of disease. It is urgent to screen biomarkers of tumour aggressiveness in order to clarify the clinical behaviour and to personalize therapy in UBC patients. Raf ...